Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

CAS No. :	117048-59-6
Formula :	C₁₈H₂₀O₅
M.W :	316.35
SMILES Code :	OC1=CC(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)=CC=C1OC
Synonyms :	CRC 87-09; Combrestatin A4; CA4
MDL No. :	MFCD03453309
InChI Key :	HVXBOLULGPECHP-WAYWQWQTSA-N
Pubchem ID :	5351344

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H301+H311+H331-H318
Precautionary Statements:	P261-P264-P270-P271-P280-P301+P310+P330-P302+P352+P312-P304+P340+P311-P305+P351+P338+P310-P403+P233-P405-P501
Class:	6.1
UN#:	2811
Packing Group:	Ⅲ

HER2-CAR-T cells	10 ng/mL		CA4P inhibits the proliferation of HER2-CAR-T cells	Mol Ther. 2020 Jan 8;28(1):75-88.
HUVECs cocultured with SMCs	10 nM	48 hours	To evaluate whether SMCs protect HUVECs from CA4P-induced cell death. Results showed that HUVECs cocultured with SMCs were resistant to CA4P.	J Clin Invest. 2005 Nov;115(11):2992-3006.
Smooth muscle cells (SMCs)	50 nM	48 hours	To assess the effect of CA4P on smooth muscle cells. Results showed that SMCs were not sensitive to CA4P, even at high concentrations.	J Clin Invest. 2005 Nov;115(11):2992-3006.
Human umbilical vein endothelial cells (HUVECs)	1, 5, 10, 20, 30, 40, 50 nM	12, 24, 36, 48 hours	To evaluate the effect of CA4P on endothelial cell proliferation. Results showed that low concentrations of CA4P (5 nM and 10 nM) significantly inhibited FGF-2– or VEGF-A–stimulated HUVEC proliferation.	J Clin Invest. 2005 Nov;115(11):2992-3006.
HT-29 (colon cancer cell line)	0.1 ng/mL or higher		CA4P inhibits the proliferation of HT-29 cells	Mol Ther. 2020 Jan 8;28(1):75-88.
SKOV3 (ovarian cancer cell line)	0.1 ng/mL or higher		CA4P inhibits the proliferation of SKOV3 cells	Mol Ther. 2020 Jan 8;28(1):75-88.
Human umbilical vascular endothelial cells (HUVECs)	0.001 ng/mL	18 hours	CA4P disrupts microtubule aggregation and causes morphological deformation in endothelial cells	Mol Ther. 2020 Jan 8;28(1):75-88.
Human umbilical vascular endothelial cells (HUVECs)	0.01 mg/mL	24 hours	CA4P inhibits HUVEC migration	Mol Ther. 2020 Jan 8;28(1):75-88.
Human umbilical vascular endothelial cells (HUVECs)	0.1 ng/mL or higher		CA4P inhibits HUVEC proliferation	Mol Ther. 2020 Jan 8;28(1):75-88.
Primary hepatocytes	0.0025–25 μM	48 hours	Evaluate the cytotoxicity of CA4-NPs on primary hepatocytes, results showed that CA4-NPs had no cytotoxicity on primary hepatocytes.	J Nanobiotechnology. 2021 May 1;19(1):124.
LO2 cells	0.0025–25 μM	48 hours	Evaluate the cytotoxicity of CA4-NPs on LO2 cells, results showed that CA4-NPs had no cytotoxicity on LO2 cells.	J Nanobiotechnology. 2021 May 1;19(1):124.
HepG2 cells	0.0025–25 μM	48 hours	Evaluate the cytotoxicity of CA4-NPs on HepG2 cells, results showed that CA4-NPs had lower cytotoxicity than CA4 in limited time due to incomplete drug release.	J Nanobiotechnology. 2021 May 1;19(1):124.
Hepa1-6 cells	0.0025–25 μM	48 hours	Evaluate the cytotoxicity of CA4-NPs on Hepa1-6 cells, results showed that CA4-NPs had lower cytotoxicity than CA4 in limited time due to incomplete drug release.	J Nanobiotechnology. 2021 May 1;19(1):124.

C57BL/6 mice	B16 melanoma model	Intravenous (CA4P), intraperitoneal (BV13 or E4G10)	5 mg/kg CA4P, 10 µg BV13 or 1 mg E4G10	Every 2 days for 8 days	To evaluate the effect of CA4P alone or in combination with anti–VE-cadherin antibodies on tumor growth and angiogenesis. Results showed that CA4P combined with anti–VE-cadherin antibodies significantly inhibited tumor growth and angiogenesis, and induced tumor necrosis.	J Clin Invest. 2005 Nov;115(11):2992-3006.
Female Balb/C mice	4T1 mammary tumor model	Intravenous injection	35 mg/kg	Once on day 12 and day 19	PLG-CA4 induces the polarization of tumor-associated macrophages (TAMs) toward the M2-like phenotype in 4T1 metastatic breast cancer. Compared to the monotherapy of PLG-CA4, inhibition of PI3Kγ attenuates the immunosuppressive effect of PLG-CA4 treatment by decreasing the number of M2-like TAMs and enhancing cytotoxic T lymphocytes (CTLs), significantly extending the mean survival time.	Adv Sci (Weinh). 2019 Apr 18;6(12):1900327
Mice	MMTV-PyMT mammary tumor model	Intraperitoneal injection	50 mg/kg	Single injection, culled 24 hours later	CA4P induced vessel narrowing, hypoxia, and hemorrhagic necrosis, accompanied by elevated tumor levels of CXCL12 and infiltration by TEMs.	J Clin Invest. 2011 May;121(5):1969-73
Mice	Myelosuppression model	Intravenous injection	25 mg/kg	Every other day	CA4P delays platelet recovery and blocks rebound thrombocytosis	J Clin Invest. 2006 Dec;116(12):3277-91
NOD-Prkdc scid IL-2rg null (NPG) mice	SKOV3 cell-derived xenograft (CDX) model	Intraperitoneal injection	100 mg/kg	Single injection	CA4P combined with HER2-CAR-T cells significantly inhibits SKOV3 tumor growth	Mol Ther. 2020 Jan 8;28(1):75-88.
C57BL/6 mice	Subcutaneous Hepa1-6 hepatic tumor models	Intravenous injection	20 mg/kg and 40 mg/kg CA4-NPs	Administered on day 1 and day 8	Evaluate the anti-tumor efficacy of CA4-NPs combined with aPD-L1 in Hepa1-6 hepatic tumor models, results showed significant reduction in tumor volume and weight, and prolonged survival time in the combination group.	J Nanobiotechnology. 2021 May 1;19(1):124.
Balb/c mice	H22 subcutaneous tumor model	Intravenous injection	45 mg/kg CA4-NPs	Single dose	CA4-NPs effectively reduced the HCC tumor burden by disrupting tumor blood vessels, inhibiting tumor cell proliferation, and enhancing tumor cell necrosis.	Theranostics. 2021 Apr 3;11(12):5955-5969
SCID mice	Bilateral subcutaneous RIF-1 tumor xenografts	Intravenous injection	10 mg/kg	Single treatment with 24-hour interval	To evaluate the therapeutic efficacy of SMSDTTS, including survival rate, tumor volume, and necrosis ratio. Results showed that the treatment group significantly prolonged survival, inhibited tumor growth, and increased tumor necrosis ratio compared to control groups.	Theranostics. 2013;3(2):127-37

{[proInfo.proName]}

CAS No.: 117048-59-6

{[proInfo.proName]}

CAS No.: 117048-59-6

Alternative Products

Product Details of Combretastatin A4

Safety of Combretastatin A4

Related Pathways of Combretastatin A4

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT00395434	Tumors	Phase 1	Completed	-	United Kingdom ... More >> Mount Vernon Hospital Northwood, Middlesex, United Kingdom, HA6 2RN Royal Marsden Hospital Sutton, Surrey, United Kingdom, SM2 5PT Less <<
NCT00507429	Anaplastic Thyroid Cancer	Phase 2 Phase 3	Terminated(Low rate of subject... More >> accrual) Less <<	-	-
NCT00003698	Unspecified Adult Solid Tumor,... More >> Protocol Specific Less <<	Phase 1	Completed	-	United Kingdom ... More >> Mount Vernon Hospital Northwood, England, United Kingdom, HA6 2RN Less <<
NCT00507429	-		Terminated(Low rate of subject... More >> accrual) Less <<	-	-
NCT00003768	Unspecified Adult Solid Tumor,... More >> Protocol Specific Less <<	Phase 1	Completed	-	United States, Ohio ... More >> Ireland Cancer Center Cleveland, Ohio, United States, 44106-5065 Less <<
NCT01305213	-		Completed	-	-
NCT00653939	Tumors	Phase 2	Completed	-	United States, California ... More >> Southbay Oncology Hematology Campbell, California, United States, 95008 Pacific Coast Hematology and Oncology Medical Group Fountain Valley, California, United States, 92708 UCLA Division of Hematology and Oncology Los Angeles, California, United States, 90095 Bay Area Cancer Research Group, LLC Pleasant Hill, California, United States, 94523 United States, Florida Boca Raton Comprehensive Cancer Center Boca Raton, Florida, United States, 21020 United States, Kentucky Kentuckiana Cancer Institute Louisville, Kentucky, United States, 40202 United States, Massachusetts Lahey Clinic Medical Center Burlington, Massachusetts, United States, 01805 United States, New Jersey The Center for Cancer and Hematologic Disease Cherry Hill, New Jersey, United States, 08003 United States, New Mexico San Juan Oncology Associates Farmington, New Mexico, United States, 87401 United States, Ohio Gabrail Cancer Center Canton, Ohio, United States, 44718 The Mark H. Zangmeister Center Columbus, Ohio, United States, 43219 Signal Point Clinical Research Middletown, Ohio, United States, 45042 United States, Virginia Blueridge Cancer Care Salem, Virginia, United States, 24153 United States, Washington Northwest Medical Specialties Tacoma, Washington, United States, 98405 United States, West Virginia Mary Babb Randolph Cancer Center-Clinical Trials Unit Morgantown, West Virginia, United States, 26506 Less <<
NCT01305213	Recurrent Fallopian Tube Carci... More >>noma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Less <<	Phase 2	Completed	-	-
NCT01052363	Central Nervous System Tumors	Phase 1	Withdrawn(No funding)	-	United States, West Virginia ... More >> MBRCC, West Virginia University Morgantown, West Virginia, United States, 26506 Less <<
NCT01023295	Polypoidal Choroidal Vasculopa... More >>thy Less <<	Phase 2	Completed	-	United States, California ... More >> OXiGENE Investigational Site Los Angeles, California, United States Hong Kong OXiGENE Investigational Site Hong Kong, Hong Kong Korea, Republic of OXiGENE Investigational Site Seoul, Korea, Republic of Singapore OXiGENE Investigational Site Singapore, Singapore Taiwan OXiGENE Investigational Site Changhua, Taiwan Less <<
NCT00077103	Head and Neck Cancer	Phase 1 Phase 2	Terminated(slow accrual)	-	United States, Michigan ... More >> Josephine Ford Cancer Center at Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, Ohio Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 United States, Pennsylvania Hillman Cancer Center at University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT00653939	-		Completed	-	-
NCT02132468	Neuroendocrine Tumors	Phase 2	Completed	-	United States, California ... More >> Stanford University School of Medicine Stanford, California, United States, 94305 United States, Kentucky Markey Cancer Center, Clinical Research Office Lexington, Kentucky, United States, 40356 United States, New York Montefiore Bronx, New York, United States, 10467 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Wisconsin Froedtert Hospital, Medicial College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Less <<
NCT02132468	-		Completed	-	-
NCT03014297	Neuroendocrine Tumors ... More >> Everolimus Less <<	Phase 1	Active, not recruiting	June 30, 2019	United States, Kentucky ... More >> University of Kentucky Markey Cancer Center Lexington, Kentucky, United States, 40502 Less <<
NCT00060242	Head and Neck Cancer	Phase 2	Completed	-	United States, Michigan ... More >> Josephine Ford Cancer Center at Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, Ohio Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 United States, Pennsylvania Hillman Cancer Center at University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT02055690	Ovarian Neoplasms ... More >> Neoplasms, Ovarian Ovarian Cancer Less <<	Phase 1 Phase 2	Terminated(Safety)	-	United Kingdom ... More >> Royal United Hospital Bath NHS Trust Bath, United Kingdom, BA1 3NG City Hospital Birmingham, United Kingdom, B18 7GH University Hospitals Bristol NHS Foundation Trust Bristol, United Kingdom, BS1 3NU University Collage London Hospitals NHS Foundation Trust London, United Kingdom, NW1 2PG The Royal Marsden NHS Foundation Trust London, United Kingdom, SM2 5PT The Christie NHS Foundation Trust Manchester, United Kingdom, M20 4BX Clatterbridge Centre for Oncology NHS Foundation Trust Merseyside, United Kingdom, CH63 4JY Mount Vernon Cancer Centre (East and North Herts NHS Trust) Middlesex, United Kingdom, HA6 2RN Freeman Hospital (Newcastle-upon-Tyne Hospitals NHS Foundation Trust) Newcastle-upon-Tyne And Wear, United Kingdom, NE7 7DN Oxford Radcliffe Hospitals NHS Trust Oxford, United Kingdom, OX3 9DU Less <<
NCT00113438	Cancer Tumor	Phase 2	Completed	-	United States, Utah ... More >> Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Less <<
NCT01701349	Anaplastic Thyroid Cancer	Phase 3	Withdrawn(Expected inability t... More >>o recruit study participants in a reasonable amount of time.) Less <<	December 2017	-
NCT01570790	Combretastatin A4 Phosphate ... More >> Age-related Macular Degeneration AMD CNV Choroidal Neovascularization Less <<	Phase 1 Phase 2	Completed	-	United States, Maryland ... More >> Wilmer Eye Institute Baltimore, Maryland, United States, 21287 Less <<
NCT02279602	Neuroendocrine Tumors	Phase 2	Completed	-	United States, California ... More >> Stanford University School of Medicine Stanford, California, United States, 94305 United States, Kentucky Markey Cancer Center, Clinical Research Office Lexington, Kentucky, United States, 40356 United States, New York Montefiore Bronx, New York, United States, 10467 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Wisconsin Froedtert Hospital, Medicial College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Less <<
NCT01423149	Choroidal Neovascularization ... More >> Myopia, Degenerative Less <<	Phase 2	Completed	-	-
NCT02641639	Platinum Resistant Ovarian Can... More >>cer Less <<	Phase 2 Phase 3	Terminated(Interim analysis fa... More >>iled to show efficacy benefit) Less <<	-	-

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	3.16mL 0.63mL 0.32mL	15.81mL 3.16mL 1.58mL	31.61mL 6.32mL 3.16mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed